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T
he dogma regarding the pathogenesis of type 2
diabetes has evolved over the last decade to
view the islet -cell as the ﬁnal determinant of
whether glucose tolerance is normal or abnor-
mal (1). While obesity and insulin resistance have reached
epidemic proportions around the world, the presence of
an appropriate compensation of insulin secretion
(“healthy -cells”) allows daylong glycemia to be indistin-
guishable from metabolically normal individuals (2). In
turn, pre-diabetes and type 2 diabetes result from progres-
sive -cell dysfunction (3). As such, an army of research-
ers worldwide is searching for the pathogenic basis of this
-cell dysfunction, along with strategies of when, and how,
to intervene. What has resulted is a reasonably good
mapping of the natural history of the -cell dysfunction,
plus a lengthy list of potential mechanisms. Most are based
on animal studies; therefore, homing in on the operative
mechanisms in humans remains a challenge. Still, there is
high conﬁdence within the -cell research arena that we
are on the right track to identifying the molecular details
of -cell compensation and failure.
Figure 1 shows the proposed stages of -cell dysfunc-
tion. It begins early, perhaps at birth, with -cells that are
programmed to be at risk to fail (“susceptible -cells”).
Indeed, the recent genome-wide scans have identiﬁed
many susceptibility genes for type 2 diabetes that likely
impact the development and ongoing homeostasis of the
mass of -cells, as well as insulin secretion and synthesis
(4). Although direct evidence is lacking, many are betting
that a lowered mass of normally functional -cells, from
genetics or environmentally based imprinting during fetal
or early life, will end up being a common cause of
susceptible -cells, based on animal (5,6) and human
(Kumar et al. [7]) studies posthemipancreatectomy show-
ing a predilection for diabetes. Eventually, -cell dysfunc-
tion (actually failed -cell compensation) occurs when the
subject is still normally glucose tolerant, resulting in a
slow rise in glycemia (8). Whether this reﬂects dysfunc-
tional -cells, a loss of -cells, or both is unknown. By the
onset of pre-diabetes, defective -cell function (glucose
unresponsivesness and impaired insulin pulsatility) and a
lowered -cell mass are both found and worsen with time
(1). Many mechanisms for the -cell dysfunction and death
are being studied, such as glucotoxicity, glucolipotoxicity,
oxidative or endoplasmic reticulum stress, amyloid inﬁl-
tration, inﬂammation, and so on.
However, there is one stage of this sequence called
“transition” (i.e., the time when insulin secretion switches
from successful to failed compensation) that has gone
relatively unstudied. In this issue of Diabetes, the article
by Chakravarthy et al. (9) may provide important insight
into this event, although that was not the original intent.
They intensively studied a mouse model of intrauterine
growth retardation (IUGR) due to haploinsufﬁciency for
fatty acid synthase (FAS), noting modest hyperglycemia
on a standard diet at 12 months of age and even worse
hyperglycemia after fat feeding compared with the wild-
type mice. The reason was defective insulin secretion and
a falling -cell mass. Importantly, this propensity to dia-
betes came without the postnatal catch-up in body weight
and insulin resistance that characterize most other models
of IUGR, which allowed the authors to conclude that
-cells were programmed for failure by events related to
the IUGR. The story became even more interesting when
they looked earlier (at 3 months) and found an opposite
phenotype.TheFASheterozygousmicewerehypoglycemic/
hyperinsulinemic on a standard diet, with a larger -cell
mass and insulin secretion that was hyperresponsive to
glucose, when they were more insulin sensitive than
age-matched wild-type mice. Furthermore, the FAS haplo-
insufﬁcient mice compensated better to fat feeding than
did wild-type mice in terms of a greater increase in -cell
mass and insulin secretion; plus, there were lower-than-
normal glucose values during a glucose challenge. So,
early on there was super -cell compensation, and later
there was failed compensation.
The authors concluded that they had discovered a body
weight–sensing mechanism during fetal development that
regulates -cell mass. As such, growth retardation feeds
back to enhance -cell mass and insulin secretion to
augment whole-body fat and protein deposition. They
supported this conclusion with a second mouse model of
IUGR, also with enhanced insulin sensitivity (muscle-
speciﬁc uncoupling protein-1 transgenic mice), that
showed the same early increases in -cell mass and
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FIG. 1. Proposed schema for the pathogenesis of type 2 diabetes that
incorporates the available literature on -cell mass and function
through the evolution from normal glucose tolerance to overt type 2
diabetes.
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-cell hyperfunction that programmed the -cells for later
failure (i.e., creating susceptible -cells).
It is impossible to know, from this study, about the
plausibility of the proposed fetal size–sensing regulatory
system for -cell mass and function. No biological details
for such an effect are known in mammals, and one can
envision fairly profound metabolic changes in fatty acid
homeostasis and cellular metabolism in the studied mice.
Instead, the concept of -cell hyperfunction programming
-cells for later failure (termed “-cell overwork” or “-cell
exhaustion”) is supported by studies over several decades
from many investigators (10), although the relevant liter-
ature is often forgotten. Hansen and Bodkin (11) per-
formed seminal studies that mapped the stages to type 2
diabetes in rhesus monkeys, ﬁnding that -cell hyper-
responsiveness for insulin was the ﬁrst identiﬁable event
preceding obesity and insulin resistance. We studied
Zucker fatty rats that are obese and normoglycemic and
noted that the compensatory increase in -cell mass
started well before the time reported by others for the
onset of insulin resistance (12). Studies in humans have
shown that insulin hypersecretion precedes insulin resis-
tance in nondiabetic obese juveniles (13), and a high
fasting insulin level independent of insulin resistance was
shown to be an important risk factor for type 2 diabetes in
Pima Indians (14). Moreover, intervention studies (15–18)
using inhibitors of insulin secretion (diazoxide, novel
ATP-sensitive K
 channel openers, and somatostatin),
so-called “-cell rest strategies” that have shown paradox-
ical improvements in -cell function in animals and hu-
mans with type 2 diabetes, have been highly inﬂuential for
the -cell overwork concept. Indeed, one wonders if the
improved -cell function after aggressive blood glucose
control using insulin that originally led to the glucose
toxicity concept (19,20) might more correctly stem from
-cell rest.
A key question is how to distinguish healthy -cell
compensation versus unhealthy increases in -cell func-
tion. Again, the study by Chakravarthy et al. (9) may
provide an important clue, as the 3-month-old FAS haplo-
insufﬁcient mice were mildly hypoglycemic basally and
during the glucose challenge after fat feeding. In other
words, the enhanced -cell mass and function, at this early
time point, were neither appropriate nor normally regu-
lated but instead resulted in a condition that is reminiscent
of the honeymoon period in type 1 diabetes, another state
of failing -cells. Whether there is a comparable phase in
human type 2 diabetes is unknown, although it was
commonly believed by clinicians years ago that 20% of
individuals presenting with type 2 diabetes had gone
through a prior period of reactive postmeal hypoglycemia.
Thus, extensive literature supports that enhanced -cell
function (and likely mass) is an early stage, and likely
causative event, in the progression to -cell failure and
type 2 diabetes. What is needed now is a better under-
standing of the biology that links -cell hyperfunction to
eventual failure, followed by the development of targeted
pharmaceuticals in order to test the concept of -cell rest
for the prevention and treatment of early type 2 diabetes.
REFERENCES
1. Leahy JL: -Cell dysfunction in type 2 diabetes mellitus. In Joslin’s
Diabetes Mellitus. 14th ed. Kahn CR, Weir GC, King GL, Jacobson AM,
Moses AL, Smith RJ, Eds. Philadelphia, Lippincott, Williams & Wilkins,
2005, p. 449–461
2. Polonsky KS, Given BD, Van Cauter E: Twenty-four-hour proﬁles and
pulsatile patterns of insulin secretion in normal and obese subjects. J Clin
Invest 81:442–448, 1988
3. Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin
secretory dysfunction and insulin resistance in the pathogenesis of type 2
diabetes mellitus. J Clin Invest 104:787–794, 1999
4. Florez JC: Newly identiﬁed loci highlight beta cell dysfunction as a key
cause of type 2 diabetes: where are the insulin resistance genes? Diabe-
tologia 51:1100–1110, 2008
5. Leahy JL, Bonner-Weir S, Weir GC: Minimal chronic hyperglycemia is a
critical determinant of impaired insulin secretion after an incomplete
pancreatectomy. J Clin Invest 81:1407–1414, 1988
6. Matveyenko AV, Veldhuis JD, Butler PC: Mechanisms of impaired fasting
glucose and glucose intolerance induced by an approximate 50% pancre-
atectomy. Diabetes 55:2347–2356, 2006
7. Kumar AF, Gruessner RWG, Seaquist ER: Risk of glucose intolerance and
diabetes in hemipancreatectomized donors selected for normal preopera-
tive glucose metabolism. Diabetes Care 31:1639–1643, 2008
8. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, DeFronzo RA: San
Antonio metabolism study. Beta-cell dysfunction and glucose intolerance:
results from the San Antonio metabolism (SAM) study. Diabetologia
47:31–39, 2004
9. Chakravarthy MV, Zhu Y, Wice WB, Coleman T, Kappan KL, Marshall CA,
McDaniel ML, Semenkovich CF: Decreased fetal size is associated with
-cell hyperfunction in early life and failure with age. Diabetes 57:2698–
2707, 2008
10. Leahy JL: -cell dysfunction with chronic hyperglycemia: the “overworked
-cell” hypothesis. Diabetes Revs 4:298–319, 1996
11. Hansen BC, Bodkin NL: Beta-cell hyperresponsiveness: earliest event in
development of diabetes in monkeys. Am J Physiol 259:R612–R617, 1990
12. Jetton TL, Lausier J, LaRock K, Trotman WE, Larmie B, Habibovic A,
Peshavaria M, Leahy JL: Mechanisms of compensatory beta-cell growth in
insulin-resistant rats: roles of Akt kinase. Diabetes 54:2294–2304, 2005
13. Le Stunff C, Bougne `res P: Early changes in postprandial insulin secretion,
not insulin sensitivity, characterize juvenile obesity. Diabetes 43:696–702,
1994
14. Weyer C, Hanson RL, Tataranni PA, Bogardus C, Pratley RE: A high fasting
plasma insulin concentration predicts type 2 diabetes independent of
insulin resistance: evidence for a pathogenic role of relative hyperinsuline-
mia. Diabetes 49:2094–2101, 2000
15. Leahy JL, Bumbalo LM, Chen C: Diazoxide causes recovery of beta-cell
glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes
43:173–179, 1994
16. Greenwood RH, Mahler RF, Hales CN: Improvement in insulin secretion in
diabetes after diazoxide. Lancet 1:444–447, 1976
17. Laedtke T, Kjems L, Porksen N, Schmitz O, Veldhuis J, Kao PC, Butler PC:
Overnight inhibition of insulin secretion restores pulsatility and proinsulin/
insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab 279:E520–
E528, 2000
18. Song SH, Rhodes CJ, Veldhuis JD, Butler PC: Diazoxide attenuates
glucose-induced defects in ﬁrst-phase insulin release and pulsatile insulin
secretion in human islets. Endocrinology 144:3399–3405, 2003
19. Turner RC, McCarthy ST, Holman RR, Harris E: Beta-cell function im-
proved by supplementing basal insulin secretion in mild diabetes. Br Med J
1:1252–1254, 1976
20. Garvey WT, Olefsky JM, Grifﬁn J, Hamman RF, Kolterman OG: The effect
of insulin treatment on insulin secretion and insulin action in type II
diabetes mellitus. Diabetes 34:222–2234, 1985
-CELL COMPENSATION AND FAILURE
2564 DIABETES, VOL. 57, OCTOBER 2008